Absci And Twist Bioscience Collaborate To Design Novel Antibody Using Generative AI
Portfolio Pulse from Benzinga Newsdesk
Absci Corporation and Twist Bioscience Corporation have announced a collaboration to design a novel therapeutic using generative AI. This partnership combines Absci's expertise in AI-driven drug creation with Twist's synthetic DNA technology.
October 31, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Absci Corporation partners with Twist Bioscience to design a novel therapeutic using generative AI, potentially enhancing its drug creation capabilities.
The collaboration with Twist Bioscience could enhance Absci's drug creation capabilities by integrating generative AI with synthetic DNA technology, potentially leading to innovative therapeutics and positive market perception.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Twist Bioscience collaborates with Absci to design a novel therapeutic using generative AI, showcasing its synthetic DNA technology.
The partnership with Absci highlights Twist Bioscience's synthetic DNA technology, potentially leading to innovative therapeutics and enhancing its market position.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80